Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: a Multicenter Study in Taiwan
Open Access
- 1 July 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (7), 3943-3949
- https://doi.org/10.1128/aac.00191-12
Abstract
A total of 403 nonduplicate isolates of Clostridium difficile were collected at three major teaching hospitals representing northern, central, and southern Taiwan from January 2005 to December 2010. Of these 403 isolates, 170 (42.2%) were presumed to be nontoxigenic due to the absence of genes for toxins A or B or binary toxin. The remaining 233 (57.8%) isolates carried toxin A and B genes, and 39 (16.7%) of these also had binary toxin genes. The MIC 90 of all isolates for fidaxomicin and rifaximin was 0.5 μg/ml (range, ≤0.015 to 0.5 μg/ml) and >128 μg/ml (range, ≤0.015 to >128 μg/ml), respectively. All isolates were susceptible to metronidazole (MIC 90 of 0.5 μg/ml; range, ≤0.03 to 4 μg/ml). Two isolates had reduced susceptibility to vancomycin (MICs, 4 μg/ml). Only 13.6% of isolates were susceptible to clindamycin (MIC of ≤2 μg/ml). Nonsusceptibility to moxifloxacin ( n = 81, 20.1%) was accompanied by single or multiple mutations in gyrA and gyrB genes in all but eight moxifloxacin-nonsusceptible isolates. Two previously unreported gyrB mutations might independently confer resistance (MIC, 16 μg/ml), Ser416 to Ala and Glu466 to Lys. Moxifloxacin-resistant isolates were cross-resistant to ciprofloxacin and levofloxacin, but some moxifloxacin-nonsusceptible isolates remained susceptible to gemifloxacin or nemonoxacin at 0.5 μg/ml. This study found the diversity of toxigenic and nontoxigenic strains of C. difficile in the health care setting in Taiwan. All isolates tested were susceptible to metronidazole and vancomycin. Fidaxomicin exhibited potent in vitro activity against all isolates tested, while the more than 10% of Taiwanese isolates with rifaximin MICs of ≥128 μg/ml raises concerns.Keywords
This publication has 38 references indexed in Scilit:
- New target for inhibition of bacterial RNA polymerase: ‘switch region’Current Opinion in Microbiology, 2011
- Clinical Clostridium difficile: Clonality and Pathogenicity Locus DiversityPLOS ONE, 2011
- Antimicrobial Susceptibilities and Molecular Epidemiology of Clinical Isolates of Clostridium difficile in TaiwanAntimicrobial Agents and Chemotherapy, 2011
- Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community HospitalsInfection Control & Hospital Epidemiology, 2011
- Quinolone Resistance: Much More than PredictedFrontiers in Microbiology, 2011
- Health Care–AssociatedClostridium difficileInfection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and MortalityClinical Infectious Diseases, 2010
- Emergence of reduced susceptibility to metronidazole in Clostridium difficileJournal of Antimicrobial Chemotherapy, 2008
- gyrAMutations in Fluoroquinolone-resistantClostridium difficilePCR-027Emerging Infectious Diseases, 2007
- Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan.2006
- Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in QuebecCMAJ : Canadian Medical Association Journal, 2005